IER3
IER3, also known as IEX-1, DIF-2, PRG1 and IEX-1L, is a membrane-associated member of the IER3 family. It acts in ERK signalling and protects cells from Fas- or tumour necrosis factor alpha-induced apoptosis. Browse Assay Genie's current range of IER3 research reagents below, or read on for the biology behind the target.
IER3, named immediate early response 3 and encoded as the radiation-inducible immediate-early gene IEX-1 protein, is thought to play a role in the ERK signalling pathway. It may do so by inhibiting the dephosphorylation of ERK by the phosphatase PP2A-PPP2R5C holoenzyme. It also acts as a downstream effector of ERK, mediating cell survival. Researchers studying phosphorylation-dependent signalling therefore often examine the IER3 protein alongside ERK pathway components.
The IER3 gene functions in protecting cells from apoptosis induced by Fas or tumour necrosis factor alpha. UniProt records the protein as membrane-associated and as a member of the IER3 family. The mouse ortholog is Ier3. The NCBI Gene summary adds a note of caution for transcript analysis: partially degraded and unspliced transcripts are found after virus infection in vitro, but these are not found in vivo and do not generate a valid protein. This is worth bearing in mind when interpreting IER3 gene expression data.
IER3 is also linked to cancer cell survival. As part of the NUPR1/RELB/IER3 survival pathway, it may give pancreatic ductal adenocarcinoma marked resistance to cell stress, such as starvation or gemcitabine treatment. The aliases IEX-1, DIF-2, PRG1 and IEX-1L all refer to this gene in the literature, so searches that cover each name give the fullest picture.
IER3 may inhibit PP2A-PPP2R5C-mediated dephosphorylation of ERK and acts as an ERK downstream effector, making it relevant to pathway regulation.
The gene protects cells from Fas- or tumour necrosis factor alpha-induced apoptosis, so it is a subject in cell death and survival studies.
As part of the NUPR1/RELB/IER3 pathway, IER3 may help pancreatic ductal adenocarcinoma resist starvation and gemcitabine treatment.
IER3 is an immediate-early gene product described as radiation-inducible, which places it within studies of how cells respond to stress.
IER3 may play a role in ERK signalling by inhibiting ERK dephosphorylation by the PP2A-PPP2R5C holoenzyme, and it acts as an ERK downstream effector mediating survival. The gene also protects cells from Fas- or tumour necrosis factor alpha-induced apoptosis.
IER3 is also called IEX-1, DIF-2, PRG1 and IEX-1L. The full gene name is immediate early response 3, and UniProt lists the protein as radiation-inducible immediate-early gene IEX-1. Check the datasheet of any product for its validated reactivity.
As a member of the NUPR1/RELB/IER3 survival pathway, IER3 may provide pancreatic ductal adenocarcinoma with strong resistance to cell stress, including starvation and gemcitabine treatment. The mouse ortholog is Ier3, which supports comparative work.
Survival pathway partners, ERK signalling components and apoptosis-related targets that may be studied alongside IER3.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P46695; product specifications from Assay Genie datasheets.